Peter Radovich

This profile gathers the share dealings of Peter Radovich across 3 companies, led by Mirum Pharmaceuticals, Inc., Global Blood Therapeutics, Inc. and Rain Therapeutics Inc. Over a trading history stretching from 17 August 2015 to 16 March 2026, the count stands at 56 filings.

Market trades split into 1 purchase (€232k) and 21 sales (€6.2M). Netting one side against the other leaves €5.9M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 17 share grants and 15 option exercises. So far in 2026, the count stands at no purchases and 4 sales.

The newest entry dates from 17 March 2026: an option exercise, in Mirum Pharmaceuticals, Inc. The clock since the last published purchase (7 January 2016) now reads 3,942 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.